The IBD Treatment Landscape: TL1A and Small Molecule Advanced Therapies

In this Gutsy Learn Series (GLS) webinar, attendees explored the evolving world of Crohn’s disease and ulcerative colitis treatments. The webinar covered the current inflammatory bowel disease (IBD) treatment landscape, including innovative options like TL1A and small molecule advanced therapies. The speakers explored how new medical advancements can impact long-term care and quality of life, combining both clinical expertise and lived experience perspectives.
 


Expert Speaker

Dr. Vipul Jairath

Dr. Vipul Jairath 
Gastroenterologist and Professor of Medicine, Schulich School of Medicine and Dentistry
Director of the IBD Clinical Trials Unit, Director of the IBD Fellowship program, Research Chair for the Department of Medicine, Schulich School of Medicine and Dentistry

Dr. Vipul Jairath is a Gastroenterologist and Professor of Medicine in the Schulich School of Medicine and Dentistry and holds the John and Susan McDonald Endowed Chair in Inflammatory Bowel Disease (IBD) Clinical Research at Western University, Canada.

Dr Jairath leads the IBD Center at University Hospital (London Health Sciences Center) and is Director of the IBD Clinical Trials Unit, Director of the IBD Fellowship program and Research Chair for the Department of Medicine, Schulich School of Medicine and Dentistry. 

esearch Chair for the Department of Medicine, Schulich School of Medicine and Dentistry. 

His research interests are centered around design, conduct and execution of clinical trials, outcome measures and index development and validation for use in clinical trials, including patient reported outcome measures, as well as methodological research in the design and analysis of clinical trials. He has over 500 peer reviewed publications. He has supervised multiple students and research fellows at undergraduate and postgraduate level. 

Dr. Jairath is principal investigator for multiple randomized controlled trials in IBD including investigator-initiated trials, collaborative trials and industry sponsored trials. He has served on multiple clinical trial steering committees, data monitoring committees and trial management groups.

Speaker with Lived Experience

Rebecca Voltan

Rebecca Voltan 
Manager of Strategy and Planning, TD

Rebecca Voltan was born and raised in Toronto, where she grew up with her parents and three older brothers in the city she is proud to still call home. She currently works in Corporate Finance as a Manager of Strategy and Planning within Global Security and Defence, where she focuses on driving clarity, alignment, and execution across complex initiatives.

Outside of work, Rebecca is an active and creative person who enjoys spending time outdoors—especially in the summer. She lives in Toronto’s west end with her husband and their two cats, and stays busy keeping up with a lively extended family that includes ten nieces and nephews. In her free time, she enjoys running, painting, volunteering, cooking, and designing spaces.

Back

  • Canada has among the highest incidence rates of Crohn's and colitis in the world.
  • 1 in 140 Canadians lives with Crohn’s or colitis.
  • Families new to Canada are developing these diseases for the first time.
  • Incidence of Crohn’s in Canadian kids under 10 has doubled since 1995.
  • People are most commonly diagnosed before age 30.

Other Areas of Interest